Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zerit + Epivir + Viramune
- Development stage
- Unknown
- Lead developer
- Makerere University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of three antiretroviral agents: stavudine (Zerit), lamivudine (Epivir), and nevirapine (Viramune). Stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that act as chain terminators during viral DNA synthesis by competing with natural substrates for incorporation into the viral DNA strand. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly and non-competitively to the HIV-1 reverse transcriptase enzyme, inducing a conformational change that inhibits its catalytic activity. This specific regimen was utilized as the innovator reference arm in a bioequivalence study conducted by Makerere University in Uganda to compare the branded individual components against the generic fixed-dose combination Triomune in HIV-infected adults.
- Brand names
- Viramune
- Other names
- stavudine + lamivudine + nevirapineZerit + Epivir + Viramune-Makerere University-HIV infection
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on Zerit + Epivir + Viramune.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zerit + Epivir + Viramune.